Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tomoaki Ikeda"'
Autor:
Hiroaki Tanaka, Junichi Hasegawa, Shinji Katsuragi, Kayo Tanaka, Tatsuya Arakaki, Masamitsu Nakamura, Eijiro Hayata, Masahiko Nakata, Akihiko Sekizawa, Isamu Ishiwata, Tomoaki Ikeda
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 8, p 2908 (2023)
Background: Unlike Europe and the United States, Japan has seen numerous maternal deaths from hemorrhagic strokes related to hypertensive disorders of pregnancy (HDP). This study retrospectively analyzed deaths associated with HDP-related hemorrhagic
Externí odkaz:
https://doaj.org/article/ccbfd17146254e539f71146dd46676a7
Autor:
Masahiko Sugimoto, Kohei Sampa, Hideyuki Tsukitome, Kumiko Kato, Hisashi Matsubara, Shin Asami, Kaori Sekimoto, Shigehiko Kitano, Shigeo Yoshida, Yoshihiro Takamura, Takao Hirano, Toshinori Murata, Miho Shimizu, Takamasa Kinoshita, Sentaro Kusuhara, Osamu Sawada, Masahito Ohji, Rina Yoshikawa, Kazuhiro Kimura, Hiroto Ishikawa, Fumi Gomi, Hiroto Terasaki, Mineo Kondo, Tomoaki Ikeda, on behalf of the Writing Committee of Japan-Clinical Retina STudy Group (J-CREST)
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 10, p 2789 (2022)
In the original publication [...]
Externí odkaz:
https://doaj.org/article/6a4e8245a5f9424fbda656b0b120dadd
Autor:
Masahiko Sugimoto, Kohei Sampa, Hideyuki Tsukitome, Kumiko Kato, Hisashi Matsubara, Shin Asami, Kaori Sekimoto, Shigehiko Kitano, Shigeo Yoshida, Yoshihiro Takamura, Takao Hirano, Toshinori Murata, Miho Shimizu, Takamasa Kinoshita, Sentaro Kusuhara, Osamu Sawada, Masahito Ohji, Rina Yoshikawa, Kazuhiro Kimura, Hiroto Ishikawa, Fumi Gomi, Hiroto Terasaki, Mineo Kondo, Tomoaki Ikeda, on behalf of the Writing Committee of Japan-Clinical Retina STudy Group (J-CREST)
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 1, p 165 (2021)
The aim of this study was to determine the prevalence and progression of diabetic retinopathy (DR) with hyperglycemic disorders during pregnancy (HDPs) in Japan between 2013 and 2018 using two cohorts. The patients with HDPs were classified as those
Externí odkaz:
https://doaj.org/article/06e4b020166145faa2a403c37b02f791
Autor:
Shintaro Maki, Ineko Kato, Naosuke Enomoto, Sho Takakura, Masafumi Nii, Kayo Tanaka, Hiroaki Tanaka, Shinsuke Hori, Kana Matsuda, Yukito Ueda, Hirofumi Sawada, Masahiro Hirayama, Akihiro Sudo, Tomoaki Ikeda
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 5, p 1448 (2020)
To assess the long-term effects of tadalafil, a therapeutic agent for fetal growth restriction (FGR), we evaluated the developmental progress of 1.5-year-old infants whose mothers had taken tadalafil during pregnancy. Twenty-four infants were assesse
Externí odkaz:
https://doaj.org/article/8b94335cdc3247c4b950f7fb83f491d7
Autor:
Shintaro Maki, Hiroaki Tanaka, Makoto Tsuji, Fumi Furuhashi, Shoichi Magawa, Michiko K. Kaneda, Masafumi Nii, Kayo Tanaka, Eiji Kondo, Satoshi Tamaru, Toru Ogura, Yuki Nishimura, Masayuki Endoh, Tadashi Kimura, Tomomi Kotani, Akihiko Sekizawa, Tomoaki Ikeda
Publikováno v:
Journal of Clinical Medicine, Vol 8, Iss 6, p 856 (2019)
Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor with a long half-life, high selectivity, and rapid onset of action. Because the safety of using PDE5 inhibitors as therapeutic agents for fetal growth restriction (FGR) has been a problem worldwide,
Externí odkaz:
https://doaj.org/article/986dc5e2f8b24488a43f44cd70f92329
Autor:
Mineo Kondo, Tomoaki Ikeda, Sentaro Kusuhara, Masahiko Sugimoto, Takamasa Kinoshita, Yoshihiro Takamura, Hiroto Ishikawa, Shigeo Yoshida, Kumiko Kato, Fumi Gomi
Publikováno v:
Journal of Clinical Medicine. 11:2789
In the original publication [...]
Autor:
Fumi Furuhashi, Yuki Nishimura, Shintaro Maki, Tadashi Kimura, Masayuki Endoh, Makoto Tsuji, Hiroaki Tanaka, Shoichi Magawa, Akihiko Sekizawa, Satoshi Tamaru, Masafumi Nii, Toru Ogura, Eiji Kondo, Kayo Tanaka, Michiko Kaneda, Tomomi Kotani, Tomoaki Ikeda
Publikováno v:
Journal of Clinical Medicine
Volume 8
Issue 6
Journal of Clinical Medicine, Vol 8, Iss 6, p 856 (2019)
Volume 8
Issue 6
Journal of Clinical Medicine, Vol 8, Iss 6, p 856 (2019)
Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor with a long half-life, high selectivity, and rapid onset of action. Because the safety of using PDE5 inhibitors as therapeutic agents for fetal growth restriction (FGR) has been a problem worldwide,